Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Chubb Ltd (CB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Chubb Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while Chubb Ltd trades at $345.1 (market cap $133.90B). The key difference: Chubb Ltd is far larger — about 4.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Chubb Ltd pays a 1.18% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CB | |
|---|---|---|
Market Cap | $29.60B | $133.90B |
Sector | Health | Financials |
52-Week High | $491.22 | $363.50 |
52-Week Low | $205.48 | $268.20 |
Enterprise Value | $27.56B | $154.74B |
Dividend Yield | — | 1.18% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →
